Загрузка...

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma

PURPOSE: Blocking the interaction between the programmed cell death (PD)-1 protein and one of its ligands, PD-L1, has been reported to have impressive antitumor responses. Therapeutics targeting this pathway are currently in clinical trials. Pembrolizumab and nivolumab are the first of this anti-PD-...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin Ther
Главные авторы: Mahoney, Kathleen M., Freeman, Gordon J., McDermott, David F.
Формат: Artigo
Язык:Inglês
Опубликовано: 2015
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4497957/
https://ncbi.nlm.nih.gov/pubmed/25823918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clinthera.2015.02.018
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!